Abstract 299P
Background
With the increasing proportion of women surviving carcinoma cervix, quality of life becomes an important issue. Most of the diagnosed women belong to the sexually active group (mean age 50 years). Therefore impact on sexual health is vital. Since there are only few studies on the topic, this study is to assess sexual dysfunction issues in patients treated with multimodality therapy using the LENT SOMA scores.
Methods
The study was prospective. A total of 85 patients were accrued comprising 6 stage IB, 6 stage II A, 25 stage II B, 2 stage IIIA, 45 stage III B and 1 stage IV A disease. Sixty six patients were treated with radiotherapy in which 46 patients received chemoradiotherapy and 19 had surgery prior to postoperative radiotherapy. The mean age was 47.81 years with a range of 2568 years. Completion of LENT SOMA scale and Statistical analysis for sexual dysfunction scores was done- stage wise and treatment wise.
Results
Mean subjective sexual function and satisfaction scores was highest in stage IIIA disease (0.0972) while maximum subjective sexual score was seen in stage IIB disease (0.94). Mean objective score VG (Vagina) was highest in stage IVA and maximum score (0.80) was seen in stage IIIB. The mean subjective sexual function and satisfaction score was highest (0.4601) in patients in which gap between treatment and interview was 11 years and maximum score was highest (0.94) in same group. The mean subjective sexual function and satisfaction score was highest (0.4601) in patients who were treated in earlier years when compared with other patients p value-0.093). Sexual function and satisfaction maximum score was highest in combined surgery and radiotherapy group (0.94) and minimum in RT alone group (0.54). The objective mean score VG (Vagina) was highest in combined surgery and radiotherapy group and maximum score(0.80) was highest in the radiotherapy(+chemo) group.
Conclusions
Currently there is no single self-report measure in routine clinical follow use which is easy to complete and incorporates all aspects of sexual health for people affected by cancer. We used LENT SOMA scale in our study, it provides a comprehensive system to assess treatment induced sexual difficulties to score the impact of radiotherapy morbidity in cervical cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
602P - COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib (Enco) + binimetinib (Bini) vs vemurafenib (Vemu) or Enco in patients (Pts) with BRAF V600-mutant melanoma
Presenter: Andrew Haydon
Session: Poster Display
Resources:
Abstract
603P - An individualised postoperative radiological surveillance schedule for IDH-wildtype glioblastoma patients (HK-GBM Registry)
Presenter: Jason Chak Yan Li
Session: Poster Display
Resources:
Abstract
604P - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who progressed after prior VEGFR-targeted therapy: Outcomes from COSMIC-311 by BRAF status
Presenter: Marcia Brose
Session: Poster Display
Resources:
Abstract
606P - BRAF and NRAS mutations are associated with poor prognosis in Asians with acral-lentiginous and nodular cutaneous melanoma
Presenter: Sumadi Lukman Anwar
Session: Poster Display
Resources:
Abstract
607P - Single institutional outcomes of radiotherapy and systemic therapy for melanoma brain metastases in Japan
Presenter: Naoya Yamazaki
Session: Poster Display
Resources:
Abstract
608P - The efficacy of immune checkpoint inhibitors and targeted therapy in mucosal melanomas: A systematic review and meta-analysis
Presenter: Andrea Teo
Session: Poster Display
Resources:
Abstract
609P - The association between thyroid function abnormalities and vitiligo induced by pembrolizumab regarding prognosis in patients with advanced melanoma
Presenter: Moez Mobarek
Session: Poster Display
Resources:
Abstract
610P - Analyzing the clinical benefit of the evidence presented at these congresses and utilizing a standardized scale to quantify it will significantly enhance our understanding of the studies showcased, allowing for more objective evaluation and interpretation
Presenter: Charles Jeffrey Tan
Session: Poster Display
Resources:
Abstract
611P - ESMO-magnitude of clinical benefit scale (MCBS) scores for phase III trials of adjuvant and curative therapies at the 2022 ASCO annual meeting (ASCO22)
Presenter: Thi Thao Vi Luong
Session: Poster Display
Resources:
Abstract
612P - Is the juice worth the squeeze? Overall survival gain per unit treatment time as a metric of clinical benefit of systemic treatment in incurable cancers
Presenter: Vodathi Bamunuarachchi
Session: Poster Display
Resources:
Abstract